Factors contributing to higher hematocrit levels in hemodialysis patients not receiving recombinant human erythropoietin

Takeda, Atsushi; Toda, Takayuki; Shinohara, Shinsuke; Mogi, Yoshiyuki; Matsui, Noriaki

doi:10.1053/ajkd.2002.33918

Cited by 30 publications

(27 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased ferritin in ESRD was also associated with a partial, inefficient response to ESA, and more severe anemia (18). Our non-ESA patients had lower values of ferritin than the ones in the ESA group, a result that matches others (2,12). TSAT was also reduced in our group, as was in another study, while others did not observe a significant difference or did not find TSAT values as predictive factors for non-ESA status (2,3,12).…”

Section: Discussionsupporting

confidence: 78%

“…Takeda et al compared an ESA group that consisted of 133 patients against a non-ESA group that had 25 patients, and found no difference regarding gender, presence of ADPKD, serum albumin (increased in the non-ESA group that we ESA-erythropoiesis-stimulating agents, BMI-body mass index, Hb-hemoglobin, IBWG-interdialytic body weight gain, PTHintact parathormone, Kt/V -spKt/V -K/DOQI formula, TSAT-transferrin saturation, SBP-predialysis systolic blood pressure, DBP-predialysis diastolic blood pressure, UDV-urea distribution volume, BVP-blood volume processed, nPCR -normalized protein catabolic ratio, CRP -C-reactive protein studied), with another study finding again that non-ESA patients had higher albumin levels (2), iron values, C-reactive protein, nPCR (no difference as well in our study), and even endogenous EPO. However, higher dialysis vintage, higher BMI, and serum leptin levels were found to be independent factors that contribute to the presence of non-ESA status (we did not find differences in BMI) (12). When comparing the two groups in our study, there was no significant difference in age and dialysis vintage, but there was one regarding gender distribution, with more men belonging to the non-ESA group.…”

Section: Discussioncontrasting

confidence: 59%

See 1 more Smart Citation

Effect of long period treatment with erythropoiesis stimulating agents on clinically and laboratory parameters in hemodialysis autosomal dominant polycystic kidney disease patients

Orășan

Petrov

Urian

et al. 2017

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 78%

Section: Discussioncontrasting

confidence: 59%

Effect of long period treatment with erythropoiesis stimulating agents on clinically and laboratory parameters in hemodialysis autosomal dominant polycystic kidney disease patients

Orășan

Petrov

Urian

et al. 2017

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

show abstract

“…BMI has been reported to be negatively associated with the control of anemia (19,20) and in the present study, EPO responsiveness was negatively correlated with BMI. However, previous studies have demonstrated that BMI was independent of the EPO response (21).…”

Section: Discussionsupporting

confidence: 71%

“…In the second stage of CKD (eGFR=60-89 mol/min/1.73 mm -2 ) (2,(16)(17)(18)(19)(20), the level of resistin increased markedly, whereas other polypeptide substances were freely filtered by the kidneys. In addition, the level of resistin was observed to increase with decreasing levels of eGFR in CKD patients.…”

Section: Discussionmentioning

confidence: 99%

Analysis of the correlation between serum resistin and the variability of erythropoietin responsiveness in patients with chronic kidney disease

Zhang

Kan

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Chronic kidney disease (CKD) is commonly accompanied by inflammation and anemia; however, the pathogenesis of CKD is unclear. Expression of resistin, a cysteine-rich secretory plasma protein, is correlated with the expression of tumor necrosis factor (TNF)-α, interleukin (IL)-6 and lipoprotein-associated phospholipase A2, indicating that resistin may be involved in inflammatory events. In addition, inflammation inhibits the activity of erythropoietin (EPO) and, thus, erythropoiesis. The aim of the present study was to analyze the correlation between serum resistin and the variability of EPO responsiveness in CKD patients. The levels of serum creatinine (SCr), C-reactive protein (CRP), total cholesterol, triglycerides, IL-6 and serum resistin were measured in the samples obtained from 138 CKD patients and healthy control subjects. The levels of serum resistin in the CKD groups with and without hemodialysis were significantly higher than those observed in the normal control group (P<0.01) and the levels of serum resistin in the hemodialysis CKD group were higher than those observed in the CKD group without dialysis (P<0.01). The levels of serum resistin in patients in the randomly selected CKD group (with hemodialysis) were positively correlated with the duration of dialysis and the levels of SCr and CRP (P<0.05), however, were negatively correlated with the estimated glomerular filtration rate. The EPO resistance index (ERI) was identified to be associated with body mass index and the levels of CRP and resistin; furthermore, EPO reactivity was correlated with the level of resistin and ERI. The levels of serum resistin were correlated with the variability in EPO responsiveness that was observed in the CKD patients. Therefore, the measurement of serum resistin may aid with understanding the mechanisms, clinical diagnosis and treatment of CKD. IntroductionChronic kidney disease (CKD), a worldwide problem with a high incidence, is commonly accompanied by inflammation and anemia. Between 6.5 and 10% of the population in developed countries suffer from various renal diseases (1). CKD is a condition, which is characterized by chronic inflammation and is hypothesized to be promoted by cytokines and oxidation reactions. The inflammation can be induced by toxins, immune complexes, microorganisms, chemical agents and complement, and is activated by the monocyte-macrophage system during which tumor necrosis factor (TNF)-α, interleukin (IL)-6 and other agents are released (1). However, the underlying pathogenesis of the numerous forms of CKD remains unclear.Expression of resistin, a cysteine-rich secretory plasma protein (molecular weight, ~12.5 kDa), is correlated with the expression of TNF-α, IL-6, lipoprotein-associated phospholipase A2 and other factors, which indicates that it may be involved in various inflammatory events. A number of studies have identified that resistin was involved in insulin resistance and metabolic syndromes in renal diseases (1-3) and CKD patients on maintenance hemodialysis often succum...

show abstract

“…Several studies demonstrated that ROSs are capable of inhibiting the production of EPO from kidney tissue. Takeda et al (Takeda et al, 2002) hypothesized that also nutritional status, probably through leptin action, may affect erythropoiesis and demonstrated that BMI and leptin were inversely correlated with rHuEPO dose required in patients receiving hemodialysis. Indeed, in vitro studies have suggested that leptin plays a role in enhancing erythropoiesis but, certainly, this hypothesis needs more definitive analysis.…”

Section: Cancer-related Anaemiamentioning

confidence: 99%

Inflammation and ovarian cancer

Macciò¹,

Madeddu²

2012

Cytokine

258

173

View full text Add to dashboard Cite

Factors contributing to higher hematocrit levels in hemodialysis patients not receiving recombinant human erythropoietin

Cited by 30 publications

References 25 publications

Effect of long period treatment with erythropoiesis stimulating agents on clinically and laboratory parameters in hemodialysis autosomal dominant polycystic kidney disease patients

Effect of long period treatment with erythropoiesis stimulating agents on clinically and laboratory parameters in hemodialysis autosomal dominant polycystic kidney disease patients

Analysis of the correlation between serum resistin and the variability of erythropoietin responsiveness in patients with chronic kidney disease

Inflammation and ovarian cancer

Contact Info

Product

Resources

About